Does the media prefer SPTX or INDV?

In the previous week, Seaport Therapeutics and Seaport Therapeutics both had 2 articles in the media. Seaport Therapeutics' average media sentiment score of 0.54 beat Indivior's score of 0.00 indicating that Seaport Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Seaport Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Indivior 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer SPTX or ARQT?

In the previous week, Arcutis Biotherapeutics had 3 more articles in the media than Seaport Therapeutics. MarketBeat recorded 5 mentions for Arcutis Biotherapeutics and 2 mentions for Seaport Therapeutics. Seaport Therapeutics' average media sentiment score of 0.54 beat Arcutis Biotherapeutics' score of 0.36 indicating that Seaport Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Seaport Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Arcutis Biotherapeutics 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor TARS or SPTX?

In the previous week, Tarsus Pharmaceuticals had 3 more articles in the media than Seaport Therapeutics. MarketBeat recorded 5 mentions for Tarsus Pharmaceuticals and 2 mentions for Seaport Therapeutics. Seaport Therapeutics' average media sentiment score of 0.54 beat Tarsus Pharmaceuticals' score of 0.22 indicating that Seaport Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tarsus Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Seaport Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer RGC or SPTX?

Seaport Therapeutics has a consensus price target of $38.57, indicating a potential upside of 108.49%. Given Seaport Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Seaport Therapeutics is more favorable than Regencell Bioscience. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Regencell Bioscience 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Seaport Therapeutics 2 Sell rating(s) 3 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 2.50

Which has higher valuation & earnings, RGC or SPTX?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Regencell Bioscience N/A N/A -$3.58M N/A N/A Seaport Therapeutics N/A N/A -$74.88M -$12.12 N/A

Is RGC or SPTX more profitable?

Company Net Margins Return on Equity Return on Assets Regencell Bioscience N/A N/A N/A Seaport Therapeutics N/A N/A N/A

Does the media refer more to RGC or SPTX?

In the previous week, Seaport Therapeutics had 1 more articles in the media than Regencell Bioscience. MarketBeat recorded 2 mentions for Seaport Therapeutics and 1 mentions for Regencell Bioscience. Seaport Therapeutics' average media sentiment score of 0.54 beat Regencell Bioscience's score of 0.00 indicating that Seaport Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Regencell Bioscience 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Seaport Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Seaport Therapeutics (SPTX) Competitors

$18.37 -0.05 (-0.27%)

As of 09:31 AM Eastern

Compare

SPTX vs. INDV, OGN, ARQT, TARS, and RGC

Should you buy Seaport Therapeutics stock or one of its competitors? Seaport Therapeutics's main competitors and comparable companies include Indivior (INDV), Organon & Co. (OGN), Arcutis Biotherapeutics (ARQT), Tarsus Pharmaceuticals (TARS), and Regencell Bioscience (RGC). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Seaport Therapeutics compare to Indivior?

Seaport Therapeutics (NASDAQ:SPTX) and Indivior (NASDAQ:INDV) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their risk, earnings, media sentiment, profitability, dividends, valuation, analyst recommendations and institutional ownership.

Indivior has higher revenue and earnings than Seaport Therapeutics. Seaport Therapeutics is trading at a lower price-to-earnings ratio than Indivior, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Seaport Therapeutics	N/A	N/A	-$74.88M	-$12.12	N/A
Indivior	$1.24B	3.43	$210M	$2.79	12.90

60.3% of Indivior shares are owned by institutional investors. 0.7% of Indivior shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Indivior has a net margin of 26.65% compared to Seaport Therapeutics' net margin of 0.00%. Seaport Therapeutics' return on equity of 0.00% beat Indivior's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Seaport Therapeutics	N/A	N/A	N/A
Indivior	26.65%	-283.11%	36.85%

Seaport Therapeutics presently has a consensus price target of $38.57, suggesting a potential upside of 108.49%. Indivior has a consensus price target of $45.17, suggesting a potential upside of 25.50%. Given Seaport Therapeutics' higher possible upside, analysts plainly believe Seaport Therapeutics is more favorable than Indivior.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Seaport Therapeutics	2 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.50
Indivior	0 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.71

In the previous week, Seaport Therapeutics and Seaport Therapeutics both had 2 articles in the media. Seaport Therapeutics' average media sentiment score of 0.54 beat Indivior's score of 0.00 indicating that Seaport Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Seaport Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Indivior	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Indivior beats Seaport Therapeutics on 9 of the 14 factors compared between the two stocks.

How does Seaport Therapeutics compare to Organon & Co.?

Seaport Therapeutics (NASDAQ:SPTX) and Organon & Co. (NYSE:OGN) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, profitability, media sentiment, institutional ownership, dividends, valuation and risk.

77.4% of Organon & Co. shares are owned by institutional investors. 1.6% of Organon & Co. shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Seaport Therapeutics currently has a consensus target price of $38.57, indicating a potential upside of 108.49%. Organon & Co. has a consensus target price of $11.40, indicating a potential downside of 16.88%. Given Seaport Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Seaport Therapeutics is more favorable than Organon & Co..

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Seaport Therapeutics	2 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.50
Organon & Co.	2 Sell rating(s)	5 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.71

Organon & Co. has a net margin of 3.41% compared to Seaport Therapeutics' net margin of 0.00%. Organon & Co.'s return on equity of 88.97% beat Seaport Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Seaport Therapeutics	N/A	N/A	N/A
Organon & Co.	3.41%	88.97%	6.03%

In the previous week, Seaport Therapeutics had 2 more articles in the media than Organon & Co.. MarketBeat recorded 2 mentions for Seaport Therapeutics and 0 mentions for Organon & Co.. Organon & Co.'s average media sentiment score of 0.57 beat Seaport Therapeutics' score of 0.54 indicating that Organon & Co. is being referred to more favorably in the news media.

Company	Overall Sentiment
Seaport Therapeutics	Positive
Organon & Co.	Positive

Organon & Co. has higher revenue and earnings than Seaport Therapeutics. Seaport Therapeutics is trading at a lower price-to-earnings ratio than Organon & Co., indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Seaport Therapeutics	N/A	N/A	-$74.88M	-$12.12	N/A
Organon & Co.	$6.22B	0.58	$187M	$0.77	17.81

Summary

Organon & Co. beats Seaport Therapeutics on 10 of the 15 factors compared between the two stocks.

How does Seaport Therapeutics compare to Arcutis Biotherapeutics?

Seaport Therapeutics (NASDAQ:SPTX) and Arcutis Biotherapeutics (NASDAQ:ARQT) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, dividends, analyst recommendations, valuation, earnings and media sentiment.

Arcutis Biotherapeutics has higher revenue and earnings than Seaport Therapeutics. Seaport Therapeutics is trading at a lower price-to-earnings ratio than Arcutis Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Seaport Therapeutics	N/A	N/A	-$74.88M	-$12.12	N/A
Arcutis Biotherapeutics	$376.07M	8.41	-$16.14M	$0.21	119.76

In the previous week, Arcutis Biotherapeutics had 3 more articles in the media than Seaport Therapeutics. MarketBeat recorded 5 mentions for Arcutis Biotherapeutics and 2 mentions for Seaport Therapeutics. Seaport Therapeutics' average media sentiment score of 0.54 beat Arcutis Biotherapeutics' score of 0.36 indicating that Seaport Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Seaport Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Arcutis Biotherapeutics	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Arcutis Biotherapeutics has a net margin of 6.15% compared to Seaport Therapeutics' net margin of 0.00%. Arcutis Biotherapeutics' return on equity of 15.05% beat Seaport Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Seaport Therapeutics	N/A	N/A	N/A
Arcutis Biotherapeutics	6.15%	15.05%	6.51%

Seaport Therapeutics presently has a consensus price target of $38.57, suggesting a potential upside of 108.49%. Arcutis Biotherapeutics has a consensus price target of $35.57, suggesting a potential upside of 41.44%. Given Seaport Therapeutics' higher probable upside, equities research analysts clearly believe Seaport Therapeutics is more favorable than Arcutis Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Seaport Therapeutics	2 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.50
Arcutis Biotherapeutics	0 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.67

Summary

Arcutis Biotherapeutics beats Seaport Therapeutics on 9 of the 12 factors compared between the two stocks.

How does Seaport Therapeutics compare to Tarsus Pharmaceuticals?

Tarsus Pharmaceuticals (NASDAQ:TARS) and Seaport Therapeutics (NASDAQ:SPTX) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, valuation, risk, dividends, institutional ownership, media sentiment, analyst recommendations and earnings.

90.0% of Tarsus Pharmaceuticals shares are held by institutional investors. 9.6% of Tarsus Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Seaport Therapeutics has a net margin of 0.00% compared to Tarsus Pharmaceuticals' net margin of -7.67%. Seaport Therapeutics' return on equity of 0.00% beat Tarsus Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tarsus Pharmaceuticals	-7.67%	-13.53%	-8.12%
Seaport Therapeutics	N/A	N/A	N/A

Tarsus Pharmaceuticals presently has a consensus target price of $100.86, indicating a potential upside of 35.45%. Seaport Therapeutics has a consensus target price of $38.57, indicating a potential upside of 108.49%. Given Seaport Therapeutics' higher possible upside, analysts clearly believe Seaport Therapeutics is more favorable than Tarsus Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tarsus Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.80
Seaport Therapeutics	2 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.50

Tarsus Pharmaceuticals has higher revenue and earnings than Seaport Therapeutics. Tarsus Pharmaceuticals is trading at a lower price-to-earnings ratio than Seaport Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tarsus Pharmaceuticals	$451.36M	7.24	-$66.42M	-$1.09	N/A
Seaport Therapeutics	N/A	N/A	-$74.88M	-$12.12	N/A

In the previous week, Tarsus Pharmaceuticals had 3 more articles in the media than Seaport Therapeutics. MarketBeat recorded 5 mentions for Tarsus Pharmaceuticals and 2 mentions for Seaport Therapeutics. Seaport Therapeutics' average media sentiment score of 0.54 beat Tarsus Pharmaceuticals' score of 0.22 indicating that Seaport Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tarsus Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Seaport Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Tarsus Pharmaceuticals beats Seaport Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Seaport Therapeutics compare to Regencell Bioscience?

Regencell Bioscience (NASDAQ:RGC) and Seaport Therapeutics (NASDAQ:SPTX) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, valuation, dividends, media sentiment, risk, profitability and institutional ownership.

Seaport Therapeutics has a consensus price target of $38.57, indicating a potential upside of 108.49%. Given Seaport Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Seaport Therapeutics is more favorable than Regencell Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Regencell Bioscience	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Seaport Therapeutics	2 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.50

0.1% of Regencell Bioscience shares are owned by institutional investors. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Seaport Therapeutics had 1 more articles in the media than Regencell Bioscience. MarketBeat recorded 2 mentions for Seaport Therapeutics and 1 mentions for Regencell Bioscience. Seaport Therapeutics' average media sentiment score of 0.54 beat Regencell Bioscience's score of 0.00 indicating that Seaport Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Regencell Bioscience	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Seaport Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Regencell Bioscience	N/A	N/A	-$3.58M	N/A	N/A
Seaport Therapeutics	N/A	N/A	-$74.88M	-$12.12	N/A

Company	Net Margins	Return on Equity	Return on Assets
Regencell Bioscience	N/A	N/A	N/A
Seaport Therapeutics	N/A	N/A	N/A

Summary

Seaport Therapeutics beats Regencell Bioscience on 6 of the 8 factors compared between the two stocks.

Get Seaport Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SPTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SPTX vs. The Competition

Export

Metric	Seaport Therapeutics	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$983.35M	$12.25B	$7.15B	$13.32B
Dividend Yield	N/A	2.65%	2.54%	17.38%
P/E Ratio	-1.52	799.72	274.34	26.21
Price / Sales	N/A	838.83	599.96	87.34
Price / Cash	N/A	15.08	27.22	34.70
Price / Book	N/A	10.66	11.07	6.40
Net Income	-$74.88M	$2.83B	$3.49B	$381.07M
7 Day Performance	-1.71%	-2.03%	-1.37%	-0.30%
1 Month Performance	-26.11%	-6.57%	-6.03%	-4.53%
1 Year Performance	N/A	-4.72%	7.25%	1.62%

Seaport Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SPTX Seaport Therapeutics	2.7348 of 5 stars	$18.37 -0.3%	$38.57 +110.0%	N/A	$983.35M	N/A	N/A	58
INDV Indivior	4.1322 of 5 stars	$35.82 -0.5%	$45.17 +26.1%	+55.3%	$4.23B	$1.24B	12.84	838
OGN Organon & Co.	1.2718 of 5 stars	$13.74 +0.1%	$11.40 -17.0%	+24.4%	$3.61B	$6.22B	17.84	10,000
ARQT Arcutis Biotherapeutics	3.8134 of 5 stars	$26.92 +2.5%	$35.57 +32.1%	+26.3%	$3.38B	$376.07M	128.20	354	News Coverage
TARS Tarsus Pharmaceuticals	3.1958 of 5 stars	$75.69 -0.4%	$100.86 +33.3%	+14.3%	$3.32B	$451.36M	N/A	50

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SPTX) was last updated on 10/6/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Seaport Therapeutics (SPTX) Competitors

SPTX vs. INDV, OGN, ARQT, TARS, and RGC

How does Seaport Therapeutics compare to Indivior?

Summary

How does Seaport Therapeutics compare to Organon & Co.?

Summary

How does Seaport Therapeutics compare to Arcutis Biotherapeutics?

Summary

How does Seaport Therapeutics compare to Tarsus Pharmaceuticals?

Summary

How does Seaport Therapeutics compare to Regencell Bioscience?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SPTX vs. The Competition

Seaport Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Seaport Therapeutics (SPTX) Competitors

SPTX vs. INDV, OGN, ARQT, TARS, and RGC

How does Seaport Therapeutics compare to Indivior?

Which has higher earnings & valuation, SPTX or INDV?

Do insiders and institutionals hold more shares of SPTX or INDV?

Is SPTX or INDV more profitable?

Do analysts recommend SPTX or INDV?

Does the media prefer SPTX or INDV?

Summary

How does Seaport Therapeutics compare to Organon & Co.?

Do insiders & institutionals believe in SPTX or OGN?

Do analysts prefer SPTX or OGN?

Is SPTX or OGN more profitable?

Does the media favor SPTX or OGN?

Which has stronger valuation & earnings, SPTX or OGN?

Summary

How does Seaport Therapeutics compare to Arcutis Biotherapeutics?

Which has stronger earnings and valuation, SPTX or ARQT?

Does the media prefer SPTX or ARQT?

Is SPTX or ARQT more profitable?

Do analysts recommend SPTX or ARQT?

Summary

How does Seaport Therapeutics compare to Tarsus Pharmaceuticals?

Do insiders and institutionals believe in TARS or SPTX?

Is TARS or SPTX more profitable?

Do analysts prefer TARS or SPTX?

Which has preferable valuation and earnings, TARS or SPTX?

Does the media favor TARS or SPTX?

Summary

How does Seaport Therapeutics compare to Regencell Bioscience?

Do analysts prefer RGC or SPTX?

Do institutionals & insiders hold more shares of RGC or SPTX?

Does the media refer more to RGC or SPTX?

Which has higher valuation & earnings, RGC or SPTX?

Is RGC or SPTX more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SPTX vs. The Competition

Seaport Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools